US7511131B2
(en)
|
2002-11-13 |
2009-03-31 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
EP2141233B1
(en)
|
2002-11-18 |
2016-10-19 |
Roche Innovation Center Copenhagen A/S |
Antisense design
|
US20050287558A1
(en)
|
2004-05-05 |
2005-12-29 |
Crooke Rosanne M |
SNPs of apolipoprotein B and modulation of their expression
|
DE102005042073B4
(de)
*
|
2005-08-31 |
2010-11-11 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Faserlaser
|
CN101437933B
(zh)
|
2005-12-28 |
2013-11-06 |
斯克里普斯研究所 |
作为药物靶标的天然反义和非编码的rna转录物
|
PL2314594T3
(pl)
*
|
2006-01-27 |
2014-12-31 |
Isis Pharmaceuticals Inc |
Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych
|
DK2363481T3
(en)
|
2006-05-05 |
2017-06-26 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating gene expression
|
EP2505648A1
(en)
*
|
2006-05-05 |
2012-10-03 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of PTP1B
|
US7666854B2
(en)
*
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
JP5441688B2
(ja)
*
|
2006-05-11 |
2014-03-12 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
5’修飾二環式核酸類似体
|
AU2007310989B2
(en)
|
2006-10-18 |
2014-05-29 |
Isis Pharmaceuticals, Inc. |
Antisense compounds
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
JP2010510807A
(ja)
|
2006-11-27 |
2010-04-08 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
高コレステロール血症を治療するための方法
|
MX2009010196A
(es)
|
2007-03-24 |
2009-11-18 |
Genzyme Corp |
Administracion de oligonucleotidos antisentido complementarios para apolipoproteina humana.
|
US8278283B2
(en)
*
|
2007-07-05 |
2012-10-02 |
Isis Pharmaceuticals, Inc. |
6-disubstituted or unsaturated bicyclic nucleic acid analogs
|
ES2439591T3
(es)
|
2007-08-15 |
2014-01-23 |
Isis Pharmaceuticals, Inc. |
Análogos de ácido nucleico de tetrahidropirano
|
WO2009061852A2
(en)
|
2007-11-09 |
2009-05-14 |
Isis Pharmaceuticals, Inc. |
Modulation of factor 9 expression
|
JP2011502514A
(ja)
|
2007-11-09 |
2011-01-27 |
アイシス ファーマシューティカルズ インコーポレイティッド |
第7因子発現の調節
|
WO2009100320A2
(en)
*
|
2008-02-07 |
2009-08-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexitol nucleic acid analogs
|
EP2282744B1
(en)
|
2008-03-21 |
2018-01-17 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucleosides and methods for their use
|
EP2274423A2
(en)
|
2008-04-04 |
2011-01-19 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
DK2285819T3
(da)
*
|
2008-04-04 |
2013-12-02 |
Isis Pharmaceuticals Inc |
Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider
|
EP2294181A4
(en)
*
|
2008-05-22 |
2013-04-24 |
Isis Pharmaceuticals Inc |
MODULATION OF SMRT EXPRESSION
|
EP2323667A4
(en)
*
|
2008-08-07 |
2012-07-25 |
Isis Pharmaceuticals Inc |
MODULATION OF TRANSTHYRETIN EXPRESSION BY TREATMENT OF CNS DISEASES
|
US8669102B2
(en)
*
|
2008-08-14 |
2014-03-11 |
Isis Pharmaceuticals, Inc. |
Modulation of prion expression
|
ES2657696T3
(es)
|
2008-08-25 |
2018-03-06 |
Excaliard Pharmaceuticals, Inc. |
Método para reducir la cicatrización durante la curación de una herida utilizando compuestos antisentido dirigidos al CTGF
|
DK2331141T3
(en)
|
2008-08-25 |
2016-04-04 |
Excaliard Pharmaceuticals Inc |
Antisense oligonucleotides WHO IS TARGETING connective tissue, AND USES THEREOF
|
US8946172B2
(en)
*
|
2008-08-25 |
2015-02-03 |
Excaliard Pharmaceuticals, Inc. |
Method for reducing scarring during wound healing using antisense compounds directed to CTGF
|
US8604192B2
(en)
*
|
2008-09-24 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Cyclohexenyl nucleic acids analogs
|
DK2356129T3
(da)
*
|
2008-09-24 |
2013-05-13 |
Isis Pharmaceuticals Inc |
Substituerede alpha-L-bicykliske nukleosider
|
MX339820B
(es)
|
2008-10-03 |
2016-06-13 |
Curna Inc |
Compuestos oligonucleottidos designados para inhibir el transcrito antisentido natrual apra apolipoproteina-a1.
|
EP2379084B1
(en)
|
2008-10-15 |
2017-11-22 |
Ionis Pharmaceuticals, Inc. |
Modulation of factor 11 expression
|
WO2010048585A2
(en)
|
2008-10-24 |
2010-04-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
RU2015151857A
(ru)
|
2008-12-02 |
2019-01-15 |
Уэйв Лайф Сайенсес Джапан, Инк. |
Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
|
US8921329B2
(en)
|
2008-12-04 |
2014-12-30 |
Curna, Inc. |
Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO
|
CN102341498B
(zh)
|
2008-12-04 |
2017-12-19 |
库尔纳公司 |
通过抑制血管内皮生长因子(vegf)的天然反义转录子治疗vegf相关的疾病
|
KR101866152B1
(ko)
|
2008-12-04 |
2018-06-08 |
큐알엔에이, 인크. |
종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
|
US9132147B2
(en)
|
2008-12-31 |
2015-09-15 |
Roche Innovation Center Copenhagen |
Use of LNA ApoB antisense oligomers for the treatment of acute coronary syndromes
|
WO2010090830A1
(en)
*
|
2009-01-20 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Modulation of sirt1 expression
|
US8536320B2
(en)
|
2009-02-06 |
2013-09-17 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
WO2010091308A2
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
EP2396038B1
(en)
|
2009-02-12 |
2015-10-21 |
CuRNA, Inc. |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
WO2010107838A1
(en)
|
2009-03-16 |
2010-09-23 |
Isis Pharmaceuticals, Inc. |
Targeting apolipoprotein b for the reduction of apolipoprotein c-iii
|
JP6116242B2
(ja)
|
2009-03-16 |
2017-04-19 |
クルナ・インコーポレーテッド |
核因子(赤血球由来2)様2(nrf2)に対する天然アンチセンス転写物の抑制によるnrf2関連疾患の治療
|
WO2010107740A2
(en)
|
2009-03-17 |
2010-09-23 |
Curna, Inc. |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
WO2010120511A2
(en)
|
2009-03-31 |
2010-10-21 |
Altair Therapeutics, Inc. |
Method of treating respiratory disorders
|
EP2427553A4
(en)
|
2009-05-06 |
2012-11-07 |
Opko Curna Llc |
TREATMENT OF LIPID TRANSPORT AND METABOLISM-RELATED DISEASES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST A LIPID TRANSPORT AND METABOLIC TREATMENT
|
JP6250930B2
(ja)
|
2009-05-06 |
2017-12-20 |
クルナ・インコーポレーテッド |
トリステトラプロリン(ttp)に対する天然アンチセンス転写物の抑制によるttp関連疾患の治療
|
JP5931720B2
(ja)
|
2009-05-08 |
2016-06-08 |
クルナ・インコーポレーテッド |
Dmdファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療
|
CN102575251B
(zh)
|
2009-05-18 |
2018-12-04 |
库尔纳公司 |
通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病
|
CA2762987A1
(en)
|
2009-05-22 |
2010-11-25 |
Joseph Collard |
Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
|
WO2010138806A2
(en)
|
2009-05-28 |
2010-12-02 |
Curna, Inc. |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
MX2011013078A
(es)
|
2009-06-12 |
2012-02-01 |
Santaris Pharma As |
Nuevos compuestos potentes antisentido anti apolipoproteina b (apob).
|
WO2010148065A2
(en)
|
2009-06-16 |
2010-12-23 |
Curna, Inc. |
Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
|
CA2765700C
(en)
|
2009-06-16 |
2021-01-05 |
Opko Curna, Llc |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
MX361732B
(es)
|
2009-06-17 |
2018-12-14 |
Cold Spring Harbor Laboratory |
Composiciones y metodos para la modulacion de division de smn2 en un sujeto.
|
US20120108800A1
(en)
|
2009-06-23 |
2012-05-03 |
Shumpei Murata |
Method for synthesizing nucleic acid
|
EP2446036B1
(en)
|
2009-06-24 |
2017-03-01 |
CuRNA, Inc. |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
CN102482672B
(zh)
|
2009-06-26 |
2016-11-09 |
库尔纳公司 |
通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
|
WO2011005761A1
(en)
|
2009-07-06 |
2011-01-13 |
Ontorii, Inc |
Novel nucleic acid prodrugs and methods use thereof
|
WO2011009697A1
(en)
|
2009-07-21 |
2011-01-27 |
Santaris Pharma A/S |
Antisense oligomers targeting pcsk9
|
WO2011011700A2
(en)
|
2009-07-24 |
2011-01-27 |
Curna, Inc. |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
KR101802536B1
(ko)
|
2009-08-05 |
2017-11-28 |
큐알엔에이, 인크. |
인슐린 유전자 (ins)에 대한 자연 안티센스 전사체의 저해에 의한 인슐린 유전자 (ins) 관련된 질환의 치료
|
EP2462153B1
(en)
|
2009-08-06 |
2015-07-29 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
ES2599986T3
(es)
|
2009-08-11 |
2017-02-06 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con adiponectina (ADIPOQ) mediante la inhibición de un transcrito antisentido natural de una adiponectina (ADIPOQ)
|
JP5943836B2
(ja)
|
2009-08-21 |
2016-07-05 |
カッパーアールエヌエー,インコーポレイテッド |
‘hsp70相互作用タンパク質c末端’(chip)に対する天然アンチセンス転写産物の阻害によるchip関連疾患の治療
|
WO2011031482A2
(en)
|
2009-08-25 |
2011-03-17 |
Curna, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
BR112012005448B1
(pt)
|
2009-09-11 |
2021-09-14 |
Ionis Pharmaceuticals, Inc |
Oligonucleotídeo modificado de fita simples direcionado a um ácido nucleico que codifica huntingtina e capaz de inibir expressão de huntingtina, composição compreendendo o mesmo e seu uso para prevenir, tratar, melhorar, e reduzir a taxa de progressão da doença de huntington
|
NO2480669T3
(US07399845-20080715-C00055.png)
|
2009-09-25 |
2018-04-07 |
|
|
EP2490699A1
(en)
|
2009-10-20 |
2012-08-29 |
Santaris Pharma A/S |
Oral delivery of therapeutically effective lna oligonucleotides
|
WO2011054811A1
(en)
|
2009-11-03 |
2011-05-12 |
Santaris Pharma A/S |
Rna antagonists targeting hsp27 combination therapy
|
US9173895B2
(en)
|
2009-12-16 |
2015-11-03 |
Curna, Inc. |
Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
|
EP2515947B1
(en)
|
2009-12-23 |
2021-10-06 |
CuRNA, Inc. |
Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
|
CN102869776B
(zh)
|
2009-12-23 |
2017-06-23 |
库尔纳公司 |
通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
|
US8962585B2
(en)
|
2009-12-29 |
2015-02-24 |
Curna, Inc. |
Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
|
CA2785173A1
(en)
|
2009-12-29 |
2011-07-28 |
Curna, Inc. |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
RU2616283C2
(ru)
|
2009-12-31 |
2017-04-13 |
Курна, Инк. |
Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2
|
ES2664605T3
(es)
|
2010-01-04 |
2018-04-20 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor 8 regulador del interferón (irf8) mediante inhibición del transcrito antisentido natural al gen irf8
|
RU2612161C2
(ru)
|
2010-01-06 |
2017-03-02 |
Курна, Инк. |
Лечение заболеваний, связанных с геном развития поджелудочной железы, путем ингибирования природного антисмыслового транскрипта к гену развития поджелудочной железы
|
CN102753186B
(zh)
|
2010-01-08 |
2016-09-14 |
Isis制药公司 |
血管生成素样3表达的调节
|
WO2011085102A1
(en)
|
2010-01-11 |
2011-07-14 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
KR101854926B1
(ko)
|
2010-01-11 |
2018-05-04 |
큐알엔에이, 인크. |
성 호르몬 결합 글로불린 (shbg)에 대한 자연 안티센스 전사체의 저해에 의한 성 호르몬 결합 글로불린 (shbg) 관련된 질환의 치료
|
EP2524038A4
(en)
*
|
2010-01-12 |
2013-11-20 |
Isis Pharmaceuticals Inc |
MODULATION OF TRANSFORMING A GROWTH FACTOR BETA-1 EXPRESSION
|
EP2529015B1
(en)
|
2010-01-25 |
2017-11-15 |
CuRNA, Inc. |
Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
|
US8957040B2
(en)
|
2010-02-08 |
2015-02-17 |
Isis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
EP3208347B1
(en)
|
2010-02-08 |
2019-08-14 |
Ionis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
RU2608496C2
(ru)
|
2010-02-22 |
2017-01-18 |
Курна, Инк. |
Лечение заболеваний, связанных с пирролин-5 карбоксилатредуктазой 1(pycr1), путем ингибирования природного антисмыслового транскрипта к pycr1
|
EP2539356A4
(en)
*
|
2010-02-26 |
2014-03-05 |
Isis Pharmaceuticals Inc |
MODULATION OF SMAD3 EXPRESSION
|
WO2011115817A1
(en)
|
2010-03-16 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
Methods of preparing 2'-o-substituted purine nucleosides
|
WO2011115818A1
(en)
|
2010-03-17 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
TWI600759B
(zh)
|
2010-04-02 |
2017-10-01 |
可娜公司 |
藉由抑制群落刺激因子3(csf3)之天然反義轉錄物以治療csf3相關疾病
|
EP3578657B1
(en)
|
2010-04-06 |
2024-03-20 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of cd274/pd-l1 gene
|
RU2610661C2
(ru)
|
2010-04-09 |
2017-02-14 |
Курна, Инк. |
Лечение заболеваний, связанных с фактором роста фибробластов 21 (fgf21), путем ингибирования природного антисмыслового транскрипта к fgf21
|
WO2011139695A2
(en)
|
2010-04-28 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
|
EP3091027B1
(en)
|
2010-04-28 |
2018-01-17 |
Ionis Pharmaceuticals, Inc. |
5' modified nucleosides and oligomeric compounds prepared therefrom
|
EP3173419A1
(en)
|
2010-04-28 |
2017-05-31 |
Ionis Pharmaceuticals, Inc. |
Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
|
EP2563920B1
(en)
|
2010-04-29 |
2017-03-15 |
Ionis Pharmaceuticals, Inc. |
Modulation of transthyretin expression
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
KR20130101442A
(ko)
|
2010-05-03 |
2013-09-13 |
큐알엔에이, 인크. |
시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
US8980858B2
(en)
|
2010-05-26 |
2015-03-17 |
Curna, Inc. |
Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA
|
ES2664572T3
(es)
|
2010-05-26 |
2018-04-20 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el homólogo atonal 1 (ATOH1) mediante inhibición del transcrito antisentido natural a ATOH1
|
JP6081910B2
(ja)
|
2010-06-02 |
2017-02-15 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
肝線維症治療用組成物および肝線維症の治療法
|
WO2011156278A1
(en)
|
2010-06-07 |
2011-12-15 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2580228B1
(en)
*
|
2010-06-08 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2011159836A2
(en)
|
2010-06-15 |
2011-12-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating interaction between proteins and target nucleic acids
|
CA2803882C
(en)
|
2010-06-23 |
2022-10-18 |
Opko Curna, Llc |
Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
|
WO2012007477A1
(en)
|
2010-07-12 |
2012-01-19 |
Santaris Pharma A/S |
Anti hcv oligomers
|
JP5998131B2
(ja)
|
2010-07-14 |
2016-09-28 |
カッパーアールエヌエー,インコーポレイテッド |
Discslargehomolog(dlg)dlg1への天然アンチセンス転写物の阻害によるdlg関連疾患の治療
|
EP3633038A3
(en)
|
2010-07-19 |
2020-07-29 |
Ionis Pharmaceuticals, Inc. |
Modulation of dystrophia myotonica-protein kinase (dmpk) expression
|
DK2601611T3
(da)
|
2010-08-02 |
2021-02-01 |
Integrated Dna Tech Inc |
Fremgangsmåder til forudsigelse af stabilitet og smeltetemperaturer for nukleinsyreduplekser
|
WO2012034942A1
(en)
|
2010-09-13 |
2012-03-22 |
Santaris Pharma A/S |
Compounds for the modulation of aurora kinase b expression
|
EP2620428B1
(en)
|
2010-09-24 |
2019-05-22 |
Wave Life Sciences Ltd. |
Asymmetric auxiliary group
|
KR101886457B1
(ko)
|
2010-10-06 |
2018-08-07 |
큐알엔에이, 인크. |
시알리다아제 4 (neu4)에 대한 자연 안티센스 전사체의 저해에 의한 neu4 관련된 질환의 치료
|
US8648053B2
(en)
|
2010-10-20 |
2014-02-11 |
Rosalind Franklin University Of Medicine And Science |
Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
|
CN103180445B
(zh)
|
2010-10-22 |
2018-02-16 |
库尔纳公司 |
通过抑制α‑L‑艾杜糖醛酸酶(IDUA)的天然反义转录物而治疗IDUA相关疾病
|
US9150864B2
(en)
|
2010-11-08 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Methods for modulating factor 12 expression
|
EP2640853B1
(en)
|
2010-11-17 |
2018-12-26 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
US10000752B2
(en)
|
2010-11-18 |
2018-06-19 |
Curna, Inc. |
Antagonat compositions and methods of use
|
WO2012066092A1
(en)
|
2010-11-19 |
2012-05-24 |
Santaris Pharma A/S |
Compounds for the modulation of aurora kinase a expression
|
WO2012066093A1
(en)
|
2010-11-19 |
2012-05-24 |
Santaris Pharma A/S |
Compounds for the modulation of pdz-binding kinase (pbk) expression
|
CA2818824A1
(en)
|
2010-11-23 |
2012-05-31 |
Joseph Collard |
Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
|
WO2012079046A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
EP2649182A4
(en)
|
2010-12-10 |
2015-05-06 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHOD FOR INCREASING AN ERYTHROPOIETIN (EPO) PREPARATION
|
TWI593416B
(zh)
|
2011-02-02 |
2017-08-01 |
艾克厘德製藥公司 |
利用針對結締組織生長因子(ctgf)目標之反義化合物治療瘢痕或肥厚性疤痕之方法
|
EP3067421B1
(en)
*
|
2011-02-08 |
2018-10-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
WO2012110457A2
(en)
|
2011-02-14 |
2012-08-23 |
Santaris Pharma A/S |
Compounds for the modulation of osteopontin expression
|
EP3674409A1
(en)
|
2011-03-29 |
2020-07-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of tmprss6 gene
|
PL2697243T3
(pl)
|
2011-04-01 |
2019-05-31 |
Ionis Pharmaceuticals Inc |
Modulacja ekspresji przekaźnika sygnału i aktywatora transkrypcji 3 (stat3)
|
AU2012242642A1
(en)
|
2011-04-13 |
2013-05-02 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
WO2012143427A1
(en)
|
2011-04-19 |
2012-10-26 |
Santaris Pharma A/S |
Anti polyomavirus compounds
|
NZ705820A
(en)
|
2011-04-21 |
2015-11-27 |
Ionis Pharmaceuticals Inc |
Modulation of hepatitis b virus (hbv) expression
|
CN103620035B
(zh)
|
2011-04-25 |
2021-04-23 |
赛诺菲 |
用于调节mir-21活性的微rna化合物以及方法
|
RU2603076C9
(ru)
|
2011-04-27 |
2017-02-03 |
Айсис Фармасьютикалс, Инк. |
Модулирование экспрессии аполипопротеина сiii (аросiii)
|
WO2012151324A1
(en)
|
2011-05-02 |
2012-11-08 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with usher syndrome
|
WO2012170347A1
(en)
|
2011-06-09 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
KR102043422B1
(ko)
|
2011-06-09 |
2019-11-11 |
큐알엔에이, 인크. |
프라탁신 (fxn)에 대한 자연 안티센스 전사체의 저해에 의한 프라탁신 (fxn) 관련된 질환의 치료
|
US9187749B2
(en)
|
2011-06-10 |
2015-11-17 |
Isis Pharmaceuticals, Inc. |
Methods for modulating factor 12 expression
|
WO2012170945A2
(en)
|
2011-06-10 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (klkb1) expression
|
AU2012271357A1
(en)
|
2011-06-16 |
2013-05-02 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of fibroblast growth factor receptor 4 expression
|
MX360782B
(es)
|
2011-06-21 |
2018-11-16 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni similares a angiopoyetina 3 (angptl3) y metodos para su uso.
|
US20140235693A1
(en)
|
2011-06-23 |
2014-08-21 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
WO2012175733A1
(en)
|
2011-06-23 |
2012-12-27 |
Santaris Pharma A/S |
Hcv combination therapy
|
WO2013003808A1
(en)
|
2011-06-29 |
2013-01-03 |
Isis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (klkb1) expression
|
US20140213632A1
(en)
|
2011-06-30 |
2014-07-31 |
Stella Aps |
HCV Combination Therapy
|
US20140113958A1
(en)
|
2011-06-30 |
2014-04-24 |
Stella Aps |
HCV Combination Therapy
|
MX347361B
(es)
|
2011-07-19 |
2017-04-12 |
Wave Life Sciences Ltd |
Metodos para la sintesis de acidos nucleicos funcionalizados.
|
EP2739735A2
(en)
|
2011-08-01 |
2014-06-11 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
EP4269584A3
(en)
|
2011-08-11 |
2024-03-27 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
EP2751269B1
(en)
|
2011-08-29 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
EP3640332A1
(en)
|
2011-08-29 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
CN108272782B
(zh)
|
2011-09-06 |
2021-04-23 |
库尔纳公司 |
小分子在制备治疗Dravet综合征或全面性癫痫伴热性惊厥附加症的药物中的用途
|
CA2848753C
(en)
|
2011-09-14 |
2022-07-26 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
ES2673721T3
(es)
|
2011-09-20 |
2018-06-25 |
Ionis Pharmaceuticals, Inc. |
Modulación antisentido de la expresión de GCGR
|
WO2013063313A1
(en)
|
2011-10-25 |
2013-05-02 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of gccr expression
|
US10202643B2
(en)
|
2011-10-31 |
2019-02-12 |
University Of Utah Research Foundation |
Genetic alterations in glioma
|
AU2012334214A1
(en)
|
2011-11-07 |
2014-05-22 |
Roche Innovation Center Copenhagen A/S |
Prognostic method for checking efficacy of micro RNA-122 inhibitors in HCV+ patients
|
WO2013068348A1
(en)
|
2011-11-07 |
2013-05-16 |
Santaris Pharma A/S |
Lna oligomers for improvement in hepatic function
|
ES2761343T3
(es)
|
2011-11-07 |
2020-05-19 |
Ionis Pharmaceuticals Inc |
Modulación de la expresión de TMPRSS6
|
CA2855241A1
(en)
|
2011-11-11 |
2013-05-16 |
Santaris Pharma A/S |
Compounds for the modulation of smn2 splicing
|
US9243291B1
(en)
|
2011-12-01 |
2016-01-26 |
Isis Pharmaceuticals, Inc. |
Methods of predicting toxicity
|
US10557136B2
(en)
|
2011-12-12 |
2020-02-11 |
Oncolmmunin Inc. |
In vivo delivery of oligonucleotides
|
CN104114572A
(zh)
|
2011-12-16 |
2014-10-22 |
现代治疗公司 |
经修饰的核苷、核苷酸和核酸组合物
|
US9546368B2
(en)
|
2011-12-22 |
2017-01-17 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1 (MALAT-1) expression
|
WO2013106770A1
(en)
|
2012-01-11 |
2013-07-18 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of ikbkap splicing
|
US9737480B2
(en)
|
2012-02-06 |
2017-08-22 |
President And Fellows Of Harvard College |
ARRDC1-mediated microvesicles (ARMMs) and uses thereof
|
US20140378533A1
(en)
|
2012-02-08 |
2014-12-25 |
Isis Pharmaceuticals, Inc. |
Modulation of rna by repeat targeting
|
CN104583405A
(zh)
|
2012-03-15 |
2015-04-29 |
科纳公司 |
通过抑制脑源神经营养因子(bdnf)的天然反义转录物治疗bdnf相关疾病
|
WO2013142514A1
(en)
|
2012-03-19 |
2013-09-26 |
Isis Pharmaceuticals, Inc. |
Methods and compositions for modulating alpha-1-antitrypsin expression
|
WO2013148283A1
(en)
|
2012-03-30 |
2013-10-03 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
|
CA2868391A1
(en)
|
2012-04-02 |
2013-10-10 |
Stephane Bancel |
Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
|
EP2833923A4
(en)
|
2012-04-02 |
2016-02-24 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
|
US9221864B2
(en)
|
2012-04-09 |
2015-12-29 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
EP2839006B1
(en)
|
2012-04-20 |
2018-01-03 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
IN2014DN09134A
(US07399845-20080715-C00055.png)
|
2012-04-25 |
2015-05-22 |
Regulus Therapeutics Inc |
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
KR102028784B1
(ko)
|
2012-05-16 |
2019-10-04 |
트랜슬레이트 바이오 인코포레이티드 |
유전자 발현을 조절하기 위한 조성물 및 방법
|
US10059941B2
(en)
|
2012-05-16 |
2018-08-28 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
US9574193B2
(en)
|
2012-05-17 |
2017-02-21 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating apolipoprotein (a) expression
|
US20160002624A1
(en)
|
2012-05-17 |
2016-01-07 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
US9518261B2
(en)
|
2012-05-22 |
2016-12-13 |
Ionis Pharmaceuticals, Inc. |
Modulation of enhancer RNA mediated gene expression
|
SI2855500T1
(sl)
|
2012-05-24 |
2020-10-30 |
Ionis Pharmaceuticals, Inc. |
Postopki in sestavki za moduliranje izražanja apolipoproteina(A)
|
WO2013181666A2
(en)
|
2012-06-01 |
2013-12-05 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
WO2013181665A1
(en)
|
2012-06-01 |
2013-12-05 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
HUE051698T2
(hu)
|
2012-06-25 |
2021-03-29 |
Ionis Pharmaceuticals Inc |
UBE3A-ATS expresszió modulálása
|
CA2879023C
(en)
|
2012-07-13 |
2017-03-28 |
Wave Life Sciences Japan |
Asymmetric auxiliary group
|
WO2014012081A2
(en)
|
2012-07-13 |
2014-01-16 |
Ontorii, Inc. |
Chiral control
|
SG11201500243WA
(en)
|
2012-07-13 |
2015-04-29 |
Shin Nippon Biomedical Lab Ltd |
Chiral nucleic acid adjuvant
|
EP3693460A1
(en)
|
2012-07-27 |
2020-08-12 |
Ionis Pharmaceuticals, Inc. |
Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
|
CN104736551B
(zh)
|
2012-08-15 |
2017-07-28 |
Ionis制药公司 |
使用改进的封端方案制备寡聚化合物的方法
|
ES2907254T3
(es)
|
2012-10-11 |
2022-04-22 |
Ionis Pharmaceuticals Inc |
Un compuesto antisentido modificado para su uso en el tratamiento de la enfermedad de Kennedy
|
EP2906699A4
(en)
|
2012-10-11 |
2016-06-08 |
Ionis Pharmaceuticals Inc |
OLIGOMER COMPOUNDS WITH BICYCLIC NUCLEOSIDES AND USES THEREOF
|
US9175291B2
(en)
|
2012-10-11 |
2015-11-03 |
Isis Pharmaceuticals Inc. |
Modulation of androgen receptor expression
|
WO2014059341A2
(en)
|
2012-10-12 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
EP3459549B1
(en)
|
2012-10-12 |
2022-04-06 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
CN104968783B
(zh)
|
2012-10-15 |
2019-12-10 |
Ionis制药公司 |
用于调节c9orf72表达的组合物
|
US10577604B2
(en)
|
2012-10-15 |
2020-03-03 |
Ionis Pharmaceuticals, Inc. |
Methods for monitoring C9ORF72 expression
|
WO2014062686A1
(en)
|
2012-10-15 |
2014-04-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating c9orf72 expression
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
US10723754B2
(en)
|
2012-10-22 |
2020-07-28 |
Idenix Pharmaceuticals Llc |
2′,4′-bridged nucleosides for HCV infection
|
SI2920308T1
(sl)
|
2012-10-31 |
2019-05-31 |
Ionis Pharmaceuticals, Inc. |
Zdravljenje raka
|
EP2914621B1
(en)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
CA2889596C
(en)
|
2012-11-15 |
2022-08-23 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugates
|
CN104903448B
(zh)
|
2012-11-26 |
2017-07-11 |
罗氏创新中心哥本哈根有限公司 |
用于调节fgfr3的表达的组合物和方法
|
US9597380B2
(en)
|
2012-11-26 |
2017-03-21 |
Modernatx, Inc. |
Terminally modified RNA
|
US9695475B2
(en)
|
2012-12-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Competitive modulation of microRNAs
|
WO2014112463A1
(ja)
*
|
2013-01-15 |
2014-07-24 |
国立大学法人大阪大学 |
スルホンアミド構造を有するヌクレオシドおよびヌクレオチド
|
WO2014113089A2
(en)
|
2013-01-17 |
2014-07-24 |
Moderna Therapeutics, Inc. |
Signal-sensor polynucleotides for the alteration of cellular phenotypes
|
US10980804B2
(en)
|
2013-01-18 |
2021-04-20 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014118272A1
(en)
|
2013-01-30 |
2014-08-07 |
Santaris Pharma A/S |
Antimir-122 oligonucleotide carbohydrate conjugates
|
DK2951305T3
(en)
|
2013-01-30 |
2018-10-29 |
Hoffmann La Roche |
LNA oligonucleotide KULHYDRATKONJUGATER
|
WO2014120861A2
(en)
|
2013-01-31 |
2014-08-07 |
Isis Pharmaceuticals, Inc. |
Method of preparing oligomeric compounds using modified coupling protocols
|
EP2951304B1
(en)
|
2013-02-04 |
2020-07-08 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
BR112015019515A8
(pt)
|
2013-02-14 |
2017-10-03 |
Isis Pharmaceuticals Inc |
Modulação da expressão de apolipoproteí-na c-iii (apociii) em populações deficientes de lipopro-teína lipase (lpld)
|
US20150366890A1
(en)
|
2013-02-25 |
2015-12-24 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
EP2968391A1
(en)
|
2013-03-13 |
2016-01-20 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
WO2014143158A1
(en)
|
2013-03-13 |
2014-09-18 |
The Broad Institute, Inc. |
Compositions and methods for labeling of agents
|
US9273349B2
(en)
|
2013-03-14 |
2016-03-01 |
Affymetrix, Inc. |
Detection of nucleic acids
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
CN111254145A
(zh)
|
2013-03-14 |
2020-06-09 |
Ionis制药公司 |
用于调节tau表达的组合物和方法
|
BR112015022621A2
(pt)
|
2013-03-14 |
2017-10-31 |
Andes Biotechnologies S A |
métodos para detecção e tratamento de mieloma múltiplo
|
US9862944B2
(en)
|
2013-03-14 |
2018-01-09 |
Andes Biotechnologies S.A. |
Antisense oligonucleotides for treatment of cancer stem cells
|
EP3312281A3
(en)
|
2013-03-14 |
2018-06-27 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
WO2014172698A1
(en)
|
2013-04-19 |
2014-10-23 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation nucleic acids through nonsense mediated decay
|
KR102214740B1
(ko)
|
2013-05-01 |
2021-02-10 |
레굴루스 테라퓨틱스 인크 |
Mir-122를 조정하기 위한 마이크로rna 화합물 및 방법
|
NZ630921A
(en)
|
2013-05-01 |
2017-12-22 |
Regulus Therapeutics Inc |
Compounds and methods for enhanced cellular uptake
|
WO2014179625A1
(en)
|
2013-05-01 |
2014-11-06 |
Isis Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION
|
AP2015008862A0
(en)
|
2013-05-22 |
2015-11-30 |
Alnylam Pharmaceuticals Inc |
Tmprss6 irna compositions and methods of use thereof
|
EP2999785B1
(en)
|
2013-05-22 |
2018-04-04 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 irna compositions and methods of use thereof
|
KR20160013110A
(ko)
|
2013-05-24 |
2016-02-03 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
B-세포 cll/림프종 11a(bcl11a)의 올리고뉴클레오티드 조절제 및 이의 용도
|
EP3004396B1
(en)
|
2013-06-06 |
2019-10-16 |
The General Hospital Corporation |
Compositions for the treatment of cancer
|
AU2014284152B2
(en)
|
2013-06-21 |
2020-01-23 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulation of target nucleic acids
|
EP3011026B1
(en)
|
2013-06-21 |
2019-12-18 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
|
HUE048738T2
(hu)
|
2013-06-27 |
2020-08-28 |
Roche Innovation Ct Copenhagen As |
Antiszensz oligomerek és konjugátumok, amelyek a PCK9-t célozzák meg
|
EP3017044B1
(en)
|
2013-07-02 |
2020-02-26 |
Ionis Pharmaceuticals, Inc. |
Modulators of growth hormone receptor
|
PT3019619T
(pt)
|
2013-07-11 |
2021-11-11 |
Modernatx Inc |
Composições que compreendem polinucleótidos sintéticos que codificam proteínas relacionadas com crispr e sgarn sintéticos e métodos de utilização
|
US10077236B2
(en)
|
2013-07-15 |
2018-09-18 |
The Regents Of The University Of California |
Azacyclic constrained analogs of FTY720
|
TWI702046B
(zh)
|
2013-07-19 |
2020-08-21 |
美商Ionis製藥公司 |
用於調節τ蛋白表現之組合物
|
EP3027617A4
(en)
|
2013-07-31 |
2017-04-12 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
SI3041854T1
(sl)
|
2013-08-08 |
2020-03-31 |
The Scripps Research Institute |
Postopek za mestnospecifično encimsko označevanje nukleinskih kislin in vitro z vključevanjem nenaravnih nukleotidov
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
KR102365486B1
(ko)
|
2013-08-28 |
2022-02-18 |
아이오니스 파마수티컬즈, 인코포레이티드 |
프리칼리크레인 (pkk) 발현의 조절
|
EP3041934A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
EP3603677A1
(en)
|
2013-09-13 |
2020-02-05 |
Ionis Pharmaceuticals, Inc. |
Modulators of complement factor b
|
US9943604B2
(en)
|
2013-09-20 |
2018-04-17 |
Ionis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
CA2925107A1
(en)
|
2013-10-02 |
2015-04-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
JP2016538829A
(ja)
|
2013-10-03 |
2016-12-15 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
低密度リポタンパク質受容体をコードするポリヌクレオチド
|
BR122020001264B1
(pt)
|
2013-10-04 |
2022-11-22 |
Icahn School Of Medicine At Mount Sinai |
Ácido ribonucleico de fita dupla (dsrna) para inibição da expressão de alas1, composição farmacêutica para inibição da expressão de um gene alas1, métodos de inibição da expressão de alas1 em uma célula e para diminuir um nível de uma porfirina ou de um precursor de porfirina em uma célula, usos de um dsrna, método para avaliar o nível de mrna de alas1 extracelular em circulação em um indivíduo, composição e uso da mesma
|
EP4166667A3
(en)
|
2013-10-11 |
2023-08-02 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating c9orf72 expression
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
US9758546B2
(en)
|
2013-10-21 |
2017-09-12 |
Ionis Pharmaceuticals, Inc. |
Method for solution phase detritylation of oligomeric compounds
|
EP3060680B1
(en)
|
2013-10-21 |
2019-02-27 |
The General Hospital Corporation |
Methods relating to circulating tumor cell clusters and the treatment of cancer
|
EP3060664B1
(en)
|
2013-10-25 |
2021-07-07 |
Sanofi |
Microrna compounds and methods for modulating mir-21 activity
|
WO2015070173A1
(en)
|
2013-11-08 |
2015-05-14 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for detecting oligonucleotides
|
ES2797679T3
(es)
|
2013-12-02 |
2020-12-03 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido y usos de los mismos
|
CA2844640A1
(en)
|
2013-12-06 |
2015-06-06 |
The University Of British Columbia |
Method for treatment of castration-resistant prostate cancer
|
BR112016013148B1
(pt)
|
2013-12-12 |
2024-02-27 |
Alnylam Pharmaceuticals, Inc |
ÁCIDO RIBONUCLEICO DE FITA DUPLA (dsRNA) PARA INIBIÇÃO DA EXPRESSÃO DO FATOR B DO COMPLEMENTO (CFB) EM UMA CÉLULA, COMPOSIÇÃO FARMACÊUTICA PARA INIBIÇÃO DA EXPRESSÃO DE UM GENE DO FATOR B DO COMPLEMENTO, SEU USO, E MÉTODO IN VITRO DE INIBIÇÃO DA EXPRESSÃO DO FATOR B DO COMPLEMENTO (CFB) EM UMA CÉLULA
|
CN111729090A
(zh)
|
2013-12-20 |
2020-10-02 |
通用医疗公司 |
与循环肿瘤细胞相关的方法和测定法
|
ES2830257T3
(es)
|
2013-12-24 |
2021-06-03 |
Ionis Pharmaceuticals Inc |
Modulación de la expresión de la proteína de tipo angiopoyetina 3
|
WO2015108047A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
US10149905B2
(en)
|
2014-01-15 |
2018-12-11 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
|
WO2015108046A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
|
EP4137572A1
(en)
|
2014-01-16 |
2023-02-22 |
Wave Life Sciences Ltd. |
Chiral design
|
EP3105331B1
(en)
|
2014-02-11 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
US10036019B2
(en)
|
2014-03-17 |
2018-07-31 |
Ionis Pharmaceuticals, Inc. |
Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2015143245A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating ataxin 2 expression
|
EP3119888B1
(en)
|
2014-03-19 |
2021-07-28 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating ataxin 2 expression
|
PL3126499T3
(pl)
|
2014-04-01 |
2020-11-30 |
Biogen Ma Inc. |
Kompozycje do modulowania ekspresji sod-1
|
ES2891738T3
(es)
|
2014-04-09 |
2022-01-31 |
Scripps Research Inst |
Incorporación de nucleósidos trifosfato no naturales o modificados a células a través de transportadores de ácido nucleico trifosfato
|
US20170044538A1
(en)
|
2014-04-17 |
2017-02-16 |
Biogen Ma Inc. |
Compositions and Methods for Modulation of SMN2 Splicing in a Subject
|
WO2015164693A1
(en)
|
2014-04-24 |
2015-10-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising alpha-beta-constrained nucleic acid
|
WO2015168172A1
(en)
|
2014-04-28 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
AU2015252858C1
(en)
|
2014-05-01 |
2021-09-16 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating Complement Factor B expression
|
DK3137091T3
(da)
|
2014-05-01 |
2021-01-25 |
Ionis Pharmaceuticals Inc |
Konjugater af modificerede antisense-oligonukleotider og anvendelse deraf til modulation af pkk-ekspression
|
EP3757215A3
(en)
|
2014-05-01 |
2021-03-17 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating growth hormone receptor expression
|
US10098959B2
(en)
|
2014-05-01 |
2018-10-16 |
Ionis Pharmaceuticals, Inc. |
Method for synthesis of reactive conjugate clusters
|
CA2946003A1
(en)
|
2014-05-01 |
2015-11-05 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating angiopoietin-like 3 expression
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
SG10202104570TA
(en)
|
2014-05-22 |
2021-06-29 |
Alnylam Pharmaceuticals Inc |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
WO2015179693A1
(en)
|
2014-05-22 |
2015-11-26 |
Isis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
KR20170031668A
(ko)
|
2014-06-02 |
2017-03-21 |
칠드런'즈 메디컬 센터 코포레이션 |
면역 조절을 위한 방법 및 조성물
|
USD766120S1
(en)
|
2014-06-09 |
2016-09-13 |
Gambro Lundia Ab |
Status light bar
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
EP4159741A1
(en)
|
2014-07-16 |
2023-04-05 |
ModernaTX, Inc. |
Method for producing a chimeric polynucleotide encoding a polypeptide having a triazole-containing internucleotide linkage
|
EP3171895A1
(en)
|
2014-07-23 |
2017-05-31 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
MA40463A
(fr)
|
2014-08-07 |
2017-06-14 |
Regulus Therapeutics Inc |
Ciblage de micro-arn pour traiter des troubles métaboliques
|
WO2016024205A1
(en)
|
2014-08-15 |
2016-02-18 |
Pfizer Inc. |
Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
|
KR20170070022A
(ko)
|
2014-08-29 |
2017-06-21 |
칠드런'즈 메디컬 센터 코포레이션 |
암의 치료를 위한 방법 및 조성물
|
WO2016040589A1
(en)
|
2014-09-12 |
2016-03-17 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
JP6867945B2
(ja)
|
2014-10-03 |
2021-05-12 |
コールド スプリング ハーバー ラボラトリー |
核内遺伝子出力の標的とされた増強
|
EP3204397A1
(en)
|
2014-10-10 |
2017-08-16 |
F. Hoffmann-La Roche AG |
Galnac phosphoramidites, nucleic acid conjugates thereof and their use
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
EP3207138B1
(en)
|
2014-10-17 |
2020-07-15 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
EP3212794B1
(en)
|
2014-10-30 |
2021-04-07 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
US9816080B2
(en)
|
2014-10-31 |
2017-11-14 |
President And Fellows Of Harvard College |
Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
US10287584B2
(en)
|
2014-11-12 |
2019-05-14 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of COMP
|
US10364433B2
(en)
|
2014-11-14 |
2019-07-30 |
The Regents Of The University Of California |
Modulation of AGPAT5 expression
|
EP3020813A1
(en)
|
2014-11-16 |
2016-05-18 |
Neurovision Pharma GmbH |
Antisense-oligonucleotides as inhibitors of TGF-R signaling
|
WO2016081444A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
US10400243B2
(en)
|
2014-11-25 |
2019-09-03 |
Ionis Pharmaceuticals, Inc. |
Modulation of UBE3A-ATS expression
|
EP4088741A1
(en)
|
2014-12-08 |
2022-11-16 |
The Board of Regents of the University of Texas System |
Lipocationic polymers and uses thereof
|
CN107208092B
(zh)
|
2014-12-16 |
2021-09-10 |
罗氏创新中心哥本哈根有限公司 |
手性毒性筛选方法
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
US10793855B2
(en)
|
2015-01-06 |
2020-10-06 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
CR20170359A
(es)
|
2015-02-04 |
2017-11-24 |
Hoffmann La Roche |
Oligómetros antisentido de tau y usos de estos
|
EP3254104B1
(en)
|
2015-02-04 |
2021-08-25 |
Bristol-Myers Squibb Company |
Methods of selecting therapeutic molecules
|
US10758558B2
(en)
|
2015-02-13 |
2020-09-01 |
Translate Bio Ma, Inc. |
Hybrid oligonucleotides and uses thereof
|
WO2016130806A2
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
WO2016138353A1
(en)
|
2015-02-26 |
2016-09-01 |
Ionis Pharmaceuticals, Inc. |
Allele specific modulators of p23h rhodopsin
|
ES2909308T3
(es)
|
2015-03-03 |
2022-05-06 |
Ionis Pharmaceuticals Inc |
Métodos para modular la expresión de MECP2
|
WO2016141236A1
(en)
|
2015-03-03 |
2016-09-09 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating mecp2 expression
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
EP3273974A4
(en)
|
2015-03-26 |
2018-11-07 |
Women and Infants Hospital of Rhode Island Inc. |
Therapy for malignant disease
|
BR112017015864A2
(pt)
|
2015-04-03 |
2018-07-31 |
Ionis Pharmaceuticals, Inc. |
compostos e métodos para modular a expressão de tmprss6
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
ES2791995T3
(es)
|
2015-04-16 |
2020-11-06 |
Ionis Pharmaceuticals Inc |
Composiciones para modular la expresión de C90RF72
|
US10407678B2
(en)
|
2015-04-16 |
2019-09-10 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
WO2016201301A1
(en)
|
2015-06-12 |
2016-12-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016205681A1
(en)
|
2015-06-19 |
2016-12-22 |
University Of Rochester |
Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
AU2016285724A1
(en)
|
2015-06-29 |
2017-11-16 |
Ionis Pharmaceuticals, Inc. |
Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
CN109477106B
(zh)
|
2015-07-10 |
2022-10-04 |
Ionis制药公司 |
二酰基甘油酰基转移酶2(dgat2)的调节剂
|
MA43072A
(fr)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
US20180201937A1
(en)
|
2015-08-04 |
2018-07-19 |
The University Of Chicago |
Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
|
KR20180043819A
(ko)
|
2015-08-24 |
2018-04-30 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
Lna-g 방법
|
WO2017040078A1
(en)
|
2015-09-02 |
2017-03-09 |
Alnylam Pharmaceuticals, Inc. |
PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
KR102641298B1
(ko)
|
2015-09-14 |
2024-03-04 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
지질양이온성 덴드리머 및 이의 용도
|
JP6853539B2
(ja)
|
2015-09-24 |
2021-03-31 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
合成スフィンゴ脂質様分子、薬物、これらの合成方法、および処置方法
|
US20180273577A1
(en)
|
2015-09-24 |
2018-09-27 |
Ionis Pharmaceuticals, Inc. |
Modulators of kras expression
|
US10533175B2
(en)
|
2015-09-25 |
2020-01-14 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating Ataxin 3 expression
|
EP3960183A1
(en)
|
2015-10-08 |
2022-03-02 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
CN108603230A
(zh)
|
2015-10-09 |
2018-09-28 |
南安普敦大学 |
基因表达的调节与蛋白质表达失调的筛选
|
US11078528B2
(en)
|
2015-10-12 |
2021-08-03 |
Advanced Cell Diagnostics, Inc. |
In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
EP3394258B1
(en)
|
2015-10-22 |
2021-09-22 |
Roche Innovation Center Copenhagen A/S |
In vitro toxicity screening assay
|
US11260073B2
(en)
|
2015-11-02 |
2022-03-01 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating C90RF72
|
EP4119569A1
(en)
|
2015-11-06 |
2023-01-18 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds for use in therapy
|
MX2018005277A
(es)
|
2015-11-06 |
2018-08-01 |
Ionis Pharmaceuticals Inc |
Modular la expresion de apolipoproteina (a).
|
BR112018007633A2
(pt)
|
2015-11-12 |
2018-11-06 |
F. Hoffmann-La Roche Ag |
oligonucleotídeos para indução de expressão de ube3a paterna
|
EP3389670A4
(en)
|
2015-12-04 |
2020-01-08 |
Ionis Pharmaceuticals, Inc. |
METHODS OF TREATING BREAST CANCER
|
WO2017106377A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
US11761007B2
(en)
|
2015-12-18 |
2023-09-19 |
The Scripps Research Institute |
Production of unnatural nucleotides using a CRISPR/Cas9 system
|
WO2017111137A1
(ja)
*
|
2015-12-22 |
2017-06-29 |
味の素株式会社 |
オリゴヌクレオチドの製造方法
|
EP3400300A4
(en)
|
2016-01-05 |
2019-08-07 |
Ionis Pharmaceuticals, Inc. |
METHODS FOR REDUCING LRRK2 EXPRESSION
|
WO2017147483A1
(en)
|
2016-02-26 |
2017-08-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
Multiplexed single molecule rna visualization with a two-probe proximity ligation system
|
WO2017152182A1
(en)
|
2016-03-04 |
2017-09-08 |
Rhode Island Hospital |
Targeting microrna for cancer treatment
|
AU2017229778A1
(en)
|
2016-03-09 |
2018-08-16 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for inhibiting PMP22 expression
|
CN114717235A
(zh)
|
2016-03-14 |
2022-07-08 |
豪夫迈·罗氏有限公司 |
用于减少pd-l1表达的寡核苷酸
|
AU2017234678A1
(en)
|
2016-03-16 |
2018-08-16 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating KEAP1
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
US11267843B2
(en)
|
2016-03-18 |
2022-03-08 |
Roche Innovation Center Copenhagen A/S |
Stereodefining L-monomers
|
US20190142856A1
(en)
|
2016-04-13 |
2019-05-16 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing c9orf72 expression
|
WO2017178656A1
(en)
|
2016-04-14 |
2017-10-19 |
Roche Innovation Center Copenhagen A/S |
TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
CN109475568A
(zh)
|
2016-05-06 |
2019-03-15 |
Ionis制药公司 |
Glp-1受体配体部分缀合的寡核苷酸及其用途
|
JP7097820B2
(ja)
*
|
2016-05-12 |
2022-07-08 |
ロシュ イノベーション センター コペンハーゲン エーエス |
ヌクレオシドまたはオリゴヌクレオチドへの、立体的に規定されたオキサザホスホリジンホスホルアミダイト単量体のカップリングの増大法
|
CA3024129A1
(en)
|
2016-05-16 |
2017-11-23 |
The Board Of Regents Of The University Of Texas System |
Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
|
JP6876383B2
(ja)
*
|
2016-06-07 |
2021-05-26 |
富士通オプティカルコンポーネンツ株式会社 |
波長可変光源
|
EP3469083A1
(en)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
EP3468981A1
(en)
|
2016-06-14 |
2019-04-17 |
Biogen MA Inc. |
Hydrophobic interaction chromatography for purification of oligonucleotides
|
CA3023514A1
(en)
|
2016-06-17 |
2017-12-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
MA45496A
(fr)
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
EP3472347B1
(en)
|
2016-06-17 |
2023-01-04 |
F. Hoffmann-La Roche AG |
In vitro nephrotoxicity screening assay
|
EP3472348B1
(en)
|
2016-06-17 |
2022-06-29 |
F. Hoffmann-La Roche AG |
In vitro nephrotoxicity screening assay
|
DK3475295T3
(da)
|
2016-06-24 |
2022-10-24 |
Scripps Research Inst |
Hidtil ukendt nukleosidtriphosphat-transportør og anvendelser deraf
|
US10519450B2
(en)
|
2016-07-01 |
2019-12-31 |
Hoffmann-La Roche Inc. |
Antisense oligonucleotides for modulating HTRA1 expression
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
AU2017296195A1
(en)
|
2016-07-11 |
2019-01-24 |
Translate Bio Ma, Inc. |
Nucleic acid conjugates and uses thereof
|
CN109844115B
(zh)
|
2016-07-15 |
2023-06-30 |
Ionis 制药公司 |
用于调节smn2的化合物和方法
|
JOP20190065A1
(ar)
|
2016-09-29 |
2019-03-28 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن tau
|
EP3518981A4
(en)
|
2016-10-03 |
2020-06-10 |
President and Fellows of Harvard College |
DELIVERING THERAPEUTIC RNAS VIA ARRDC1-MEDIATED MICROVESICLES
|
WO2018067900A1
(en)
|
2016-10-06 |
2018-04-12 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
US20190284621A1
(en)
|
2016-11-11 |
2019-09-19 |
Roche Innovation Center Copenhagen A/S |
Therapeutic oligonucleotides capture and detection
|
TW202313978A
(zh)
|
2016-11-23 |
2023-04-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
WO2018102397A1
(en)
|
2016-11-29 |
2018-06-07 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
EP3548620A4
(en)
|
2016-12-02 |
2020-07-22 |
Cold Spring Harbor Laboratory |
MODULATION OF THE EXPRESSION OF LNC05
|
SG10201913552UA
(en)
|
2016-12-16 |
2020-03-30 |
Alnylam Pharmaceuticals Inc |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
US20190338286A1
(en)
|
2017-01-13 |
2019-11-07 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rel expression
|
EP3568480A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb2 expression
|
WO2018130581A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rela expression
|
EP3568481A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating relb expression
|
EP3568479A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb1 expression
|
WO2018165564A1
(en)
|
2017-03-09 |
2018-09-13 |
Ionis Pharmaceuticals, Inc. |
Morpholino modified oligomeric compounds
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
US11591362B2
(en)
|
2017-03-29 |
2023-02-28 |
Roche Innovation Center Copenhagen A/S |
Orthogonal protecting groups for the preparation of stereodefined phosphorothioate oligonucleotides
|
EP3612219A1
(en)
|
2017-04-18 |
2020-02-26 |
Alnylam Pharmaceuticals, Inc. |
Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
|
US20190055564A1
(en)
|
2017-06-01 |
2019-02-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
US11401519B2
(en)
|
2017-06-07 |
2022-08-02 |
University Of Massachusetts |
Anti-ADAM33 oligonucleotides and related methods
|
WO2019002237A1
(en)
|
2017-06-28 |
2019-01-03 |
Roche Innovation Center Copenhagen A/S |
METHOD OF MULTIPLE COUPLING AND OXIDATION
|
EP3652316A4
(en)
|
2017-07-11 |
2021-04-07 |
Synthorx, Inc. |
INTEGRATION OF NON-NATURAL NUCLEOTIDES AND METHOD FOR THEREFORE
|
CA3069868A1
(en)
|
2017-07-13 |
2019-01-17 |
Alnylam Pharmaceuticals Inc. |
Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
|
MX2020001332A
(es)
|
2017-08-03 |
2020-09-09 |
Synthorx Inc |
Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas.
|
WO2019030313A2
(en)
|
2017-08-11 |
2019-02-14 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
|
WO2019036613A1
(en)
|
2017-08-18 |
2019-02-21 |
Ionis Pharmaceuticals, Inc. |
MODULATION OF THE NOTCH SIGNALING PATHWAY FOR THE TREATMENT OF RESPIRATORY DISORDERS
|
WO2019038228A1
(en)
|
2017-08-22 |
2019-02-28 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
|
CA3073515A1
(en)
|
2017-08-25 |
2019-02-28 |
Stoke Therapeutics, Inc. |
Antisense oligomers for treatment of conditions and diseases
|
US10517889B2
(en)
|
2017-09-08 |
2019-12-31 |
Ionis Pharmaceuticals, Inc. |
Modulators of SMAD7 expression
|
EP3694995A1
(en)
|
2017-10-13 |
2020-08-19 |
Roche Innovation Center Copenhagen A/S |
Methods for identifying improved stereodefined phosphorothioate oligonucleotide variants of antisense oligonucleotides utilising sub-libraries of partially stereodefined oligonucleotides
|
JP2021500013A
(ja)
|
2017-10-16 |
2021-01-07 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
B型肝炎感染の治療用のPAPD5及びPAPD7 mRNAを低減させるための核酸分子
|
SG11202002940QA
(en)
|
2017-11-01 |
2020-04-29 |
Alnylam Pharmaceuticals Inc |
Complement component c3 irna compositions and methods of use thereof
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
WO2019099610A1
(en)
|
2017-11-16 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
EP3714054A1
(en)
|
2017-11-20 |
2020-09-30 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
EP3724333A2
(en)
|
2017-12-11 |
2020-10-21 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating fndc3b expression
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
EP4257691A3
(en)
|
2017-12-14 |
2024-01-10 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
BR112020012088A2
(pt)
|
2017-12-18 |
2020-11-17 |
Alnylam Pharmaceuticals, Inc. |
composições de irna do grupo de elevada mobilidade box-1 (hmgb1) e métodos de uso dos mesmos
|
CA3085211A1
(en)
|
2017-12-21 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Companion diagnostic for htra1 rna antagonists
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
US11597926B2
(en)
|
2017-12-22 |
2023-03-07 |
Roche Innovation Center Copenhagen A/S |
Thiophosphoramidites
|
KR20200104345A
(ko)
|
2017-12-22 |
2020-09-03 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
포스포로디티오에이트 뉴클레오시드간 연결을 포함하는 올리고뉴클레오티드
|
AU2018386527A1
(en)
|
2017-12-22 |
2020-04-30 |
Roche Innovation Center Copenhagen A/S |
Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
US20210095274A1
(en)
|
2018-01-10 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating pias4 expression
|
CN112424353A
(zh)
|
2018-01-12 |
2021-02-26 |
罗氏创新中心哥本哈根有限公司 |
α-突触核蛋白反义寡核苷酸及其用途
|
CN111556894A
(zh)
|
2018-01-12 |
2020-08-18 |
哥本哈根罗氏创新中心 |
用于调控gsk3b表达的寡核苷酸
|
JP2021510511A
(ja)
|
2018-01-12 |
2021-04-30 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
アルファ−シヌクレインを標的とするアンチセンスオリゴヌクレオチドおよびその使用
|
MX2020007433A
(es)
|
2018-01-12 |
2020-09-14 |
Bristol Myers Squibb Co |
Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos.
|
JP2021511072A
(ja)
|
2018-01-15 |
2021-05-06 |
アイオニス・ファーマシューティカルズ・インコーポレイテッドIonis Pharmaceuticals,Inc. |
Dnm2発現のモジュレーター
|
EP3740574A1
(en)
|
2018-01-17 |
2020-11-25 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating erc1 expression
|
EP3740573A1
(en)
|
2018-01-18 |
2020-11-25 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting srebp1
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
MA51795A
(fr)
|
2018-02-09 |
2020-12-16 |
Hoffmann La Roche |
Oligonucléotides pour moduler l'expression de tmem106b
|
CA3090901A1
(en)
|
2018-02-12 |
2019-08-15 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
EP3755800A1
(en)
|
2018-02-21 |
2020-12-30 |
Bristol-Myers Squibb Company |
Camk2d antisense oligonucleotides and uses thereof
|
SG11202007728QA
(en)
|
2018-02-26 |
2020-09-29 |
Synthorx Inc |
Il-15 conjugates and uses thereof
|
AU2019228607B2
(en)
|
2018-03-02 |
2024-03-07 |
Ionis Pharmaceuticals, Inc. |
Modulators of IRF4 expression
|
US11732260B2
(en)
|
2018-03-02 |
2023-08-22 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of amyloid-β precursor protein
|
JPWO2019182037A1
(ja)
|
2018-03-20 |
2021-03-11 |
国立大学法人東京工業大学 |
毒性が低減されたアンチセンスオリゴヌクレオチド
|
WO2019183440A1
(en)
|
2018-03-22 |
2019-09-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating fmr1 expression
|
EP3775208A1
(en)
|
2018-04-05 |
2021-02-17 |
F. Hoffmann-La Roche AG |
Use of fubp1 inhibitors for treating hepatitis b virus infection
|
CN112292457A
(zh)
|
2018-04-09 |
2021-01-29 |
领先细胞医疗诊断有限公司 |
用于原位检测核酸的进一步增强信号放大的方法
|
JP7275164B2
(ja)
|
2018-04-11 |
2023-05-17 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Ezh2発現の調節因子
|
US20210269851A1
(en)
|
2018-05-07 |
2021-09-02 |
Roche Innovation Center Copenhagen A/S |
Massively parallel discovery methods for oligonucleotide therapeutics
|
WO2019215175A1
(en)
|
2018-05-08 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
MX2020011913A
(es)
|
2018-05-09 |
2021-01-29 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para la reduccion de la expresion de fxi.
|
MX2020011911A
(es)
|
2018-05-09 |
2021-01-29 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para reducir de la expresion de atxn3.
|
TW202016304A
(zh)
|
2018-05-14 |
2020-05-01 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
JP2021524450A
(ja)
|
2018-05-18 |
2021-09-13 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
マイクロrna関連疾患の処置のための薬学的組成物
|
WO2019224172A1
(en)
|
2018-05-25 |
2019-11-28 |
Roche Innovation Center Copenhagen A/S |
Novel process for making allofuranose from glucofuranose
|
WO2019233921A1
(en)
|
2018-06-05 |
2019-12-12 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating atxn2 expression
|
EP3807411A4
(en)
|
2018-06-14 |
2022-08-03 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR ENHANCING STMN2 EXPRESSION
|
TWI833770B
(zh)
|
2018-06-27 |
2024-03-01 |
美商Ionis製藥公司 |
用於減少 lrrk2 表現之化合物及方法
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
JP7102557B2
(ja)
|
2018-07-03 |
2022-07-19 |
エフ.ホフマン-ラ ロシュ アーゲー |
Tau発現調節用オリゴヌクレオチド
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
PE20211306A1
(es)
|
2018-07-13 |
2021-07-20 |
Hoffmann La Roche |
Oligonucleotidos para modular la expresion de rtel1
|
MX2021000922A
(es)
|
2018-07-25 |
2021-03-31 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para reducir la expresion de la atxn2.
|
KR20210041537A
(ko)
|
2018-07-31 |
2021-04-15 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
포스포로트리티오에이트 뉴클레오사이드간 연결을 포함하는 올리고뉴클레오타이드
|
MX2021001019A
(es)
|
2018-07-31 |
2021-04-19 |
Roche Innovation Ct Copenhagen As |
Oligonucleotidos que comprenden enlace internucleosidico de fosforotritioato.
|
AR114551A1
(es)
|
2018-08-13 |
2020-09-16 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE AGENTES DE ARNhd CONTRA EL VIRUS DE HEPATITIS B (HBV) Y MÉTODOS PARA SU USO
|
BR112021002779A2
(pt)
|
2018-08-15 |
2021-05-04 |
Illumina, Inc. |
composições e métodos para melhorar o enriquecimento de bibliotecas
|
US11987792B2
(en)
|
2018-08-16 |
2024-05-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
BR112021003224A2
(pt)
|
2018-08-20 |
2021-07-20 |
Rogcon, Inc. |
oligonucleotídeos antissentido direcionados a scn2a para o tratamento de encefalopatias por scn1a
|
WO2020038968A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Microrna-134 biomarker
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
JP2021536239A
(ja)
|
2018-08-28 |
2021-12-27 |
ロシュ イノベーション センター コペンハーゲン エーエス |
スプライス調節化合物を使用したネオアンチゲン操作
|
EP3620519A1
(en)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
|
EP3620520A1
(en)
|
2018-09-10 |
2020-03-11 |
Universidad del Pais Vasco |
Novel target to treat a metabolic disease in an individual
|
EP3853364A1
(en)
|
2018-09-18 |
2021-07-28 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
TW202023573A
(zh)
|
2018-09-19 |
2020-07-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
EP3873920A1
(en)
|
2018-11-01 |
2021-09-08 |
F. Hoffmann-La Roche AG |
Antisense oligonucleotides targeting tia1
|
JP2022512975A
(ja)
*
|
2018-11-08 |
2022-02-07 |
アリゴス セラピューティクス インコーポレイテッド |
S-抗原輸送阻害オリゴヌクレオチドポリマーおよび方法
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
PE20211869A1
(es)
|
2018-11-15 |
2021-09-21 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresion de irf5
|
KR20210093970A
(ko)
|
2018-11-21 |
2021-07-28 |
아이오니스 파마수티컬즈, 인코포레이티드 |
프리온 발현을 감소시키기 위한 화합물 및 방법
|
JP7467457B2
(ja)
|
2018-11-22 |
2024-04-15 |
ロシュ イノベーション センター コペンハーゲン エーエス |
立体的に規定されたオリゴヌクレオチドの合成における活性化物質としてのピリジニウム塩
|
WO2020109343A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Combination therapy for treatment of macular degeneration
|
WO2020109344A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Occular administration device for antisense oligonucleotides
|
SI3897672T1
(sl)
|
2018-12-20 |
2024-02-29 |
Humabs Biomed Sa |
Kombinirana terapija HBV
|
JP2022515744A
(ja)
|
2018-12-20 |
2022-02-22 |
プラクシス プレシジョン メディシンズ, インコーポレイテッド |
Kcnt1関連障害の治療のための組成物及び方法
|
JP2022514648A
(ja)
|
2018-12-21 |
2022-02-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Card9を標的とするアンチセンスオリゴヌクレオチド
|
WO2020150431A1
(en)
|
2019-01-16 |
2020-07-23 |
Genzyme Corporation |
Serpinc1 irna compositions and methods of use thereof
|
EP3914232A1
(en)
|
2019-01-25 |
2021-12-01 |
F. Hoffmann-La Roche AG |
Lipid vesicle for oral drug delivery
|
SG11202107399WA
(en)
|
2019-01-31 |
2021-08-30 |
Ionis Pharmaceuticals Inc |
Modulators of yap1 expression
|
KR20210123299A
(ko)
|
2019-02-06 |
2021-10-13 |
신톡스, 인크. |
Il-2 콘쥬게이트 및 이의 사용 방법
|
JP2022520663A
(ja)
|
2019-02-15 |
2022-03-31 |
アドヴァンスド セル ダイアグノスティクス,インコーポレイテッド |
in situハイブリダイゼーションによって、核酸をマルチプレックス検出する方法
|
CA3130431A1
(en)
|
2019-02-20 |
2020-08-27 |
Roche Innovation Center Copenhagen A/S |
Phosphonoacetate gapmer oligonucleotides
|
AU2020225336A1
(en)
|
2019-02-20 |
2021-08-19 |
Roche Innovation Center Copenhagen A/S |
Novel phosphoramidites
|
EP3931348B1
(en)
|
2019-02-26 |
2023-08-09 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide formulation method
|
US11279932B2
(en)
|
2019-02-27 |
2022-03-22 |
Ionis Pharmaceuticals, Inc. |
Modulators of MALAT1 expression
|
CN113507942A
(zh)
|
2019-03-05 |
2021-10-15 |
豪夫迈·罗氏有限公司 |
分子的细胞内靶向
|
AU2020241903A1
(en)
|
2019-03-21 |
2021-10-14 |
Lonza Sales Ag |
Extracellular vesicle conjugates and uses thereof
|
WO2020191177A1
(en)
|
2019-03-21 |
2020-09-24 |
Sudhir Agrawal |
Antisense oligonucleotides for allele specificity
|
KR20210144822A
(ko)
|
2019-03-29 |
2021-11-30 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Ube3a-ats를 조절하기 위한 화합물 및 방법
|
CA3198063A1
(en)
|
2019-03-29 |
2020-10-08 |
Mitsubishi Tanabe Pharma Corporation |
Compound, method and pharmaceutical composition for modulating expression of dux4
|
WO2020206115A2
(en)
|
2019-04-03 |
2020-10-08 |
Bristol-Myers Squibb Company |
Angptl2 antisense oligonucleotides and uses thereof
|
JP7499267B2
(ja)
|
2019-04-04 |
2024-06-13 |
エフ. ホフマン-ラ ロシュ アーゲー |
Atxn2発現を調節するためのオリゴヌクレオチド
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
EP3956340A1
(en)
|
2019-04-16 |
2022-02-23 |
Roche Innovation Center Copenhagen A/S |
Novel process for preparing nucleotide p(v) monomers
|
CN113767108A
(zh)
|
2019-04-30 |
2021-12-07 |
罗氏创新中心哥本哈根有限公司 |
制备铼螯合mag3寡核苷酸的新方法
|
BR112021021686A2
(pt)
|
2019-05-03 |
2022-03-22 |
Dicerna Pharmaceuticals Inc |
Moléculas inibidoras de ácido nucleico de fita dupla com fitas senso curtas
|
WO2020227395A2
(en)
|
2019-05-06 |
2020-11-12 |
University Of Massachusetts |
Anti-c9orf72 oligonucleotides and related methods
|
SG11202112240VA
(en)
|
2019-05-13 |
2021-12-30 |
Vir Biotechnology Inc |
Compositions and methods for treating hepatitis b virus (hbv) infection
|
TW202111123A
(zh)
|
2019-05-28 |
2021-03-16 |
美商Ionis製藥公司 |
用於減少fus 表現之化合物及方法
|
JP7155302B2
(ja)
|
2019-06-06 |
2022-10-18 |
エフ.ホフマン-ラ ロシュ アーゲー |
Atxn3を標的とするアンチセンスオリゴヌクレオチド
|
CA3143330A1
(en)
|
2019-06-14 |
2020-12-17 |
The Scripps Research Institute |
Reagents and methods for replication, transcription, and translation in semi-synthetic organisms
|
EP3956450A4
(en)
|
2019-07-26 |
2022-11-16 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR MODULATION OF GFAP
|
EP4007811A2
(en)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Carboxypeptidase b2 (cpb2) irna compositions and methods of use thereof
|
EP4007812A1
(en)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Serpin family f member 2 (serpinf2) irna compositions and methods of use thereof
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
CN114641570A
(zh)
|
2019-08-14 |
2022-06-17 |
科迪亚克生物科学公司 |
具有靶向kras的反义寡核苷酸的细胞外囊泡
|
US20230193274A1
(en)
|
2019-08-14 |
2023-06-22 |
Codiak Biosciences, Inc. |
Extracellular vesicles with stat3-antisense oligonucleotides
|
CA3147680A1
(en)
|
2019-08-14 |
2021-02-18 |
Dalia BURZYN |
Extracellular vesicle-aso constructs targeting stat6
|
AU2020330133A1
(en)
|
2019-08-14 |
2022-03-17 |
Lonza Sales Ag |
Extracellular vesicle-ASO constructs targeting CEBP/beta
|
CN114829586A
(zh)
|
2019-08-14 |
2022-07-29 |
科迪亚克生物科学公司 |
细胞外囊泡-nlrp3拮抗剂
|
KR20220078565A
(ko)
|
2019-08-14 |
2022-06-10 |
코디악 바이오사이언시즈, 인크. |
분자에 연결된 세포외 소포 및 이의 용도
|
JP2022544587A
(ja)
|
2019-08-15 |
2022-10-19 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
結合修飾オリゴマー化合物及びその使用
|
WO2021030706A1
(en)
|
2019-08-15 |
2021-02-18 |
Synthorx, Inc. |
Immuno oncology combination therapies with il-2 conjugates
|
MX2022002053A
(es)
|
2019-08-23 |
2022-03-17 |
Synthorx Inc |
Conjugados de il-15 y sus usos.
|
JP2022546570A
(ja)
|
2019-09-03 |
2022-11-04 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Lect2遺伝子の発現を阻害するための組成物および方法
|
EP4028060A1
(en)
|
2019-09-10 |
2022-07-20 |
Synthorx, Inc. |
Il-2 conjugates and methods of use to treat autoimmune diseases
|
WO2021062058A1
(en)
|
2019-09-25 |
2021-04-01 |
Codiak Biosciences, Inc. |
Sting agonist comprising exosomes for treating neuroimmunological disorders
|
WO2021067747A1
(en)
|
2019-10-04 |
2021-04-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
WO2021074772A1
(en)
|
2019-10-14 |
2021-04-22 |
Astrazeneca Ab |
Modulators of pnpla3 expression
|
WO2021076828A1
(en)
|
2019-10-18 |
2021-04-22 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
AR120267A1
(es)
|
2019-10-22 |
2022-02-09 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C3 DEL COMPLEMENTO Y SUS MÉTODOS DE USO
|
WO2021087325A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
EP4051795A1
(en)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
CA3156405A1
(en)
|
2019-11-04 |
2021-05-14 |
Synthorx, Inc. |
Interleukin 10 conjugates and uses thereof
|
MX2022005692A
(es)
|
2019-11-13 |
2022-06-08 |
Alnylam Pharmaceuticals Inc |
Metodos y composiciones para el tratamiento de un trastorno asociado con angiotensinogeno (agt).
|
WO2021102373A1
(en)
|
2019-11-22 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
AU2020402885A1
(en)
|
2019-12-13 |
2022-06-16 |
Alnylam Pharmaceuticals, Inc. |
Human chromosome 9 open reading frame 72 (C9orf72) iRNA agent compositions and methods of use thereof
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
CN115516091A
(zh)
|
2019-12-19 |
2022-12-23 |
豪夫迈·罗氏有限公司 |
Cops3抑制剂用于治疗乙型肝炎病毒感染的用途
|
JP2023506546A
(ja)
|
2019-12-19 |
2023-02-16 |
エフ. ホフマン-ラ ロシュ エージー. |
B型肝炎ウイルス感染症を処置するためのsept9阻害剤の使用
|
EP4077671A1
(en)
|
2019-12-19 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Use of saraf inhibitors for treating hepatitis b virus infection
|
CN114829601A
(zh)
|
2019-12-19 |
2022-07-29 |
豪夫迈·罗氏有限公司 |
Sbds抑制剂用于治疗乙型肝炎病毒感染的用途
|
CN114829599A
(zh)
|
2019-12-19 |
2022-07-29 |
豪夫迈·罗氏有限公司 |
Scamp3抑制剂用于治疗乙型肝炎病毒感染的用途
|
JP7288052B2
(ja)
|
2019-12-20 |
2023-06-06 |
エフ. ホフマン-ラ ロシュ アーゲー |
Scn9a発現を阻害するための増強されたオリゴヌクレオチド
|
JP2023509870A
(ja)
|
2019-12-24 |
2023-03-10 |
エフ. ホフマン-ラ ロシュ アーゲー |
Hbvの処置のためのhbvを標的とする治療用オリゴヌクレオチドとtlr7アゴニストとの医薬組合せ
|
JP2023509872A
(ja)
|
2019-12-24 |
2023-03-10 |
エフ. ホフマン-ラ ロシュ アーゲー |
Hbvを標的とする抗ウイルス剤及び/又はhbvの処置のための免疫調節剤の医薬組合せ
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
WO2021158810A1
(en)
|
2020-02-05 |
2021-08-12 |
Bristol-Myers Squibb Company |
Oligonucleotides for splice modulation of camk2d
|
AU2021220765A1
(en)
|
2020-02-10 |
2022-09-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing VEGF-A expression
|
JP2023514336A
(ja)
|
2020-02-18 |
2023-04-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
アポリポタンパク質C3(APOC3)iRNA組成物およびその使用法
|
JP2023516142A
(ja)
|
2020-02-28 |
2023-04-18 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Cd73エクソン7スプライシングを調節するためのオリゴヌクレオチド
|
CR20220485A
(es)
|
2020-02-28 |
2022-11-10 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para modular smn2
|
CN116096420A
(zh)
|
2020-03-02 |
2023-05-09 |
田边三菱制药株式会社 |
利用miR-33b抑制物质的动脉瘤的预防或治疗
|
WO2021178607A1
(en)
|
2020-03-05 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
EP4114948A1
(en)
|
2020-03-06 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
IL296106A
(en)
|
2020-03-06 |
2022-11-01 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of transthyretin (ttr)
|
WO2021184021A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting pmp22
|
WO2021184020A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Methods of treating neuroinflammation
|
WO2021188611A1
(en)
|
2020-03-18 |
2021-09-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
TW202204615A
(zh)
|
2020-03-26 |
2022-02-01 |
美商阿尼拉製藥公司 |
冠狀病毒iRNA組成物及其使用方法
|
WO2021202443A2
(en)
|
2020-03-30 |
2021-10-07 |
Alnylam Pharmaceucticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
IL297121A
(en)
|
2020-04-06 |
2022-12-01 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for silencing myoc expression
|
US20230159933A1
(en)
|
2020-04-07 |
2023-05-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
EP4133076A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
CA3181400A1
(en)
|
2020-04-27 |
2021-11-04 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
|
CA3181198A1
(en)
|
2020-04-30 |
2021-11-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
MX2022013707A
(es)
|
2020-05-01 |
2022-12-07 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular atxn1.
|
JP2023525770A
(ja)
|
2020-05-11 |
2023-06-19 |
ジェネンテック, インコーポレイテッド |
神経学的疾患を処置するための補体c4阻害剤および関連する組成物、ならびにそれを使用するシステムおよび方法
|
CN115551519A
(zh)
|
2020-05-11 |
2022-12-30 |
基因泰克公司 |
用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法
|
EP4150085A1
(en)
|
2020-05-11 |
2023-03-22 |
Genentech, Inc. |
Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
|
KR20230022409A
(ko)
|
2020-05-11 |
2023-02-15 |
스톡 테라퓨틱스, 인크. |
병태 및 질환의 치료를 위한 opa1 안티센스 올리고머
|
EP4151237A1
(en)
|
2020-05-12 |
2023-03-22 |
Mitsubishi Tanabe Pharma Corporation |
Compound, method and pharmaceutical composition for regulating expression of ataxin 3
|
CN116096888A
(zh)
|
2020-05-13 |
2023-05-09 |
豪夫迈·罗氏有限公司 |
靶向颗粒蛋白前体的寡核苷酸激动剂
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
EP4150086A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
EP4150088A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
EP4150089A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
WO2021231680A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
EP4150087A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
EP4150090A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
WO2021237097A1
(en)
|
2020-05-21 |
2021-11-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
JP2023526096A
(ja)
|
2020-05-22 |
2023-06-20 |
エフ. ホフマン-ラ ロシュ アーゲー |
Card9のスプライス調節のためのオリゴヌクレオチド
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
EP4162050A1
(en)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
EP4162047A1
(en)
|
2020-06-09 |
2023-04-12 |
Roche Innovation Center Copenhagen A/S |
Guanosine analogues for use in therapeutic polynucleotides
|
CA3184289A1
(en)
|
2020-06-18 |
2021-12-23 |
Alnylam Pharmaceuticals, Inc. |
Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
|
BR112022026316A2
(pt)
|
2020-06-24 |
2023-03-07 |
Vir Biotechnology Inc |
Anticorpos neutralizantes do vírus da hepatite b engenheirados e usos dos mesmos
|
MX2022016254A
(es)
|
2020-06-25 |
2023-04-11 |
Synthorx Inc |
Terapia de combinación de inmunooncología con conjugados de il-2 y anticuerpos anti-egfr.
|
AR122731A1
(es)
|
2020-06-26 |
2022-10-05 |
Hoffmann La Roche |
Oligonucleótidos mejorados para modular la expresión de fubp1
|
CN116096899A
(zh)
|
2020-06-29 |
2023-05-09 |
Ionis制药公司 |
调节plp1的化合物和方法
|
JPWO2022014703A1
(US07399845-20080715-C00055.png)
|
2020-07-17 |
2022-01-20 |
|
|
TW202219273A
(zh)
|
2020-07-23 |
2022-05-16 |
瑞士商赫孚孟拉羅股份公司 |
靶向rna結合蛋白位點之寡核苷酸
|
WO2022018155A1
(en)
|
2020-07-23 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotides for splice modulation of stmn2
|
CN116157522A
(zh)
|
2020-08-21 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
A1cf抑制剂用于治疗乙型肝炎病毒感染的用途
|
TW202227102A
(zh)
|
2020-09-22 |
2022-07-16 |
瑞典商阿斯特捷利康公司 |
治療脂肪肝病之方法
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
TW202229552A
(zh)
|
2020-10-05 |
2022-08-01 |
美商艾拉倫製藥股份有限公司 |
G蛋白-偶合受體75(GPR75)iRNA組成物及其使用方法
|
WO2022076596A1
(en)
|
2020-10-06 |
2022-04-14 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting stat6
|
BR112023006024A2
(pt)
|
2020-10-09 |
2023-05-09 |
Synthorx Inc |
Terapias de imuno-oncologia com conjugados de il-2
|
IL301611A
(en)
|
2020-10-09 |
2023-05-01 |
Synthorx Inc |
Combined immuno-oncology treatment with pairs of IL-2 and pembrolizumab
|
WO2022087041A1
(en)
|
2020-10-21 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
EP4232582A1
(en)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
JP2023549500A
(ja)
|
2020-11-13 |
2023-11-27 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
凝固第V因子(F5)iRNA組成物およびその使用方法
|
KR20230108728A
(ko)
|
2020-11-18 |
2023-07-18 |
아이오니스 파마수티컬즈, 인코포레이티드 |
앤지오텐시노겐 발현을 조절하기 위한 화합물 및 방법
|
AU2021384225A1
(en)
|
2020-11-18 |
2023-07-06 |
Lemba Bv |
Umlilo antisense transcription inhibitors
|
US20240002853A1
(en)
|
2020-11-23 |
2024-01-04 |
Alpha Anomeric Sas |
Nucleic acid duplexes
|
US11987795B2
(en)
|
2020-11-24 |
2024-05-21 |
The Broad Institute, Inc. |
Methods of modulating SLC7A11 pre-mRNA transcripts for diseases and conditions associated with expression of SLC7A11
|
TW202237150A
(zh)
|
2020-12-01 |
2022-10-01 |
美商艾拉倫製藥股份有限公司 |
用於抑制hao1(羥基酸氧化酶1(乙醇酸氧化酶))基因表現的方法及組成物
|
WO2022117745A1
(en)
|
2020-12-03 |
2022-06-09 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
WO2022117747A2
(en)
|
2020-12-03 |
2022-06-09 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
WO2022125490A1
(en)
|
2020-12-08 |
2022-06-16 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
CN116568696A
(zh)
|
2020-12-08 |
2023-08-08 |
豪夫迈·罗氏有限公司 |
二硫代磷酸酯寡核苷酸的新颖合成
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
JP2023553710A
(ja)
|
2020-12-18 |
2023-12-25 |
エフ. ホフマン-ラ ロシュ アーゲー |
プログラニュリンを標的とするためのアンチセンスオリゴヌクレオチド
|
WO2022136140A1
(en)
|
2020-12-22 |
2022-06-30 |
F. Hoffmann-La Roche Ag |
Oligonucleotides targeting xbp1
|
EP4274896A1
(en)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component 9 (c9) irna compositions and methods of use thereof
|
TW202246500A
(zh)
|
2021-02-02 |
2022-12-01 |
瑞士商赫孚孟拉羅股份公司 |
用於抑制 rtel1 表現之增強型寡核苷酸
|
WO2022174101A1
(en)
|
2021-02-12 |
2022-08-18 |
Synthorx, Inc. |
Skin cancer combination therapy with il-2 conjugates and cemiplimab
|
EP4291243A1
(en)
|
2021-02-12 |
2023-12-20 |
Synthorx, Inc. |
Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
|
TW202305131A
(zh)
|
2021-02-12 |
2023-02-01 |
美商艾拉倫製藥股份有限公司 |
用於治療或預防超氧歧化酶1-(SOD1-)相關的神經退化疾病的超氧歧化酶1(SOD1)iRNA組成物及其使用方法
|
EP4294421A2
(en)
|
2021-02-17 |
2023-12-27 |
Lonza Sales AG |
Extracellular vesicle-nlrp3 antagonist
|
IL305176A
(en)
|
2021-02-17 |
2023-10-01 |
Lonza Sales Ag |
An extracellular vesicle is linked to a biologically active molecule via an optimal linker and an anchored moiety
|
JP2024509783A
(ja)
|
2021-02-25 |
2024-03-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
プリオンタンパク質(prnp)irna組成物およびその使用方法
|
KR20230150844A
(ko)
|
2021-02-26 |
2023-10-31 |
알닐람 파마슈티칼스 인코포레이티드 |
케토헥소키나아제(KHK) iRNA 조성물 및 이의 사용 방법
|
WO2022187435A1
(en)
|
2021-03-04 |
2022-09-09 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
EP4305169A1
(en)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
BR112023019981A2
(pt)
|
2021-03-29 |
2023-12-12 |
Alnylam Pharmaceuticals Inc |
Composições do agente irna de huntingtina (htt) e métodos de uso das mesmas
|
AU2022249318A1
(en)
|
2021-03-31 |
2023-10-12 |
Entrada Therapeutics, Inc. |
Cyclic cell penetrating peptides
|
EP4314293A1
(en)
|
2021-04-01 |
2024-02-07 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
EP4304566A1
(en)
|
2021-04-01 |
2024-01-17 |
Lonza Sales AG |
Extracellular vesicle compositions
|
WO2022214632A1
(en)
|
2021-04-07 |
2022-10-13 |
Neoplants Sas |
Compositions and methods for indoor air remediation
|
JP2024517686A
(ja)
|
2021-04-26 |
2024-04-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
膜貫通プロテアーゼ、セリン6(TMPRSS6)iRNA組成物およびその使用方法
|
EP4330396A1
(en)
|
2021-04-29 |
2024-03-06 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
EP4331606A1
(en)
|
2021-04-30 |
2024-03-06 |
Kyoto University |
Prevention or treatment of myopathy using mir-33b inhibitor
|
WO2022240721A1
(en)
|
2021-05-10 |
2022-11-17 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
|
CA3217463A1
(en)
|
2021-05-10 |
2022-11-17 |
Ziqing QIAN |
Compositions and methods for modulating mrna splicing
|
KR20240012425A
(ko)
|
2021-05-10 |
2024-01-29 |
엔트라다 테라퓨틱스, 인크. |
세포내 치료제를 위한 조성물 및 방법
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
EP4341405A1
(en)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
CA3221935A1
(en)
|
2021-05-29 |
2022-12-08 |
1Globe Health Institute Llc |
Asymmetric short duplex dna as a novel gene silencing technology and use thereof
|
EP4347828A1
(en)
|
2021-05-29 |
2024-04-10 |
1Globe Health Institute LLC |
Short duplex dna as a novel gene silencing technology and use thereof
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
WO2022256395A1
(en)
|
2021-06-02 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
TW202313679A
(zh)
|
2021-06-03 |
2023-04-01 |
美商欣爍克斯公司 |
包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
|
KR20240017911A
(ko)
|
2021-06-04 |
2024-02-08 |
알닐람 파마슈티칼스 인코포레이티드 |
인간 염색체 9 개방 해독 프레임 72(C9orf72) iRNA 제제 조성물 및 이의 사용 방법
|
AR126070A1
(es)
|
2021-06-08 |
2023-09-06 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
|
AR126085A1
(es)
|
2021-06-08 |
2023-09-13 |
Hoffmann La Roche |
Agonistas de progranulina de oligonucleótido
|
EP4105328A1
(en)
|
2021-06-15 |
2022-12-21 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Antisense-oligonucleotides for prevention of kidney dysfunction promoted by endothelial dysfunction by ephrin-b2 suppression
|
BR112023026050A2
(pt)
|
2021-06-18 |
2024-03-05 |
Ionis Pharmaceuticals Inc |
Compostos e métodos para reduzir expressão de ifnar1
|
EP4359006A1
(en)
|
2021-06-23 |
2024-05-01 |
Entrada Therapeutics, Inc. |
Antisense compounds and methods for targeting cug repeats
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
EP4363574A1
(en)
|
2021-06-29 |
2024-05-08 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
KR20240026203A
(ko)
|
2021-06-30 |
2024-02-27 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐(agt)-관련 장애를 치료하는 방법 및 조성물
|
EP4373934A1
(en)
|
2021-07-19 |
2024-05-29 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
|
EP4373933A1
(en)
|
2021-07-23 |
2024-05-29 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
EP4377458A1
(en)
|
2021-07-29 |
2024-06-05 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
IL310244A
(en)
|
2021-08-03 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
Transthyretin (TTR) IRNA compositions and methods of using them
|
TW202337474A
(zh)
|
2021-08-04 |
2023-10-01 |
美商艾拉倫製藥股份有限公司 |
用於緘默血管收縮素原(AGT)的iRNA組成物及方法
|
BR112024001923A2
(pt)
|
2021-08-13 |
2024-04-30 |
Alnylam Pharmaceuticals Inc |
Composições de irna de fator xii (f12) e métodos de usos das mesmas
|
WO2023021046A1
(en)
|
2021-08-16 |
2023-02-23 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
WO2023034870A2
(en)
|
2021-09-01 |
2023-03-09 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing dmpk expression
|
CA3229661A1
(en)
|
2021-09-01 |
2023-03-09 |
Xiang Li |
Compounds and methods for skipping exon 44 in duchenne muscular dystrophy
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
WO2023044094A1
(en)
|
2021-09-20 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
CN118019848A
(zh)
|
2021-09-29 |
2024-05-10 |
豪夫迈·罗氏有限公司 |
Rna编辑
|
AU2022356427A1
(en)
|
2021-09-30 |
2024-05-09 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
WO2023069603A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
TW202334418A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓(HTT)iRNA劑組成物及其使用方法
|
TW202333749A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
補體因子b(cfb)irna組成物及其使用方法
|
WO2023078883A1
(en)
|
2021-11-03 |
2023-05-11 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating apolipoprotein e4 expression
|
WO2023086292A2
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Gata4-targeted therapeutics for treatment of cardiac hypertrophy
|
WO2023086295A2
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Antisense oligonucleotides for modifying protein expression
|
WO2023083906A2
(en)
|
2021-11-11 |
2023-05-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combinations for treatment of hbv
|
WO2023104693A1
(en)
|
2021-12-07 |
2023-06-15 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting actl6b
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
WO2023111210A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
Combination of oligonucleotides for modulating rtel1 and fubp1
|
WO2023111336A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
Oligonucleotide gba agonists
|
WO2023117738A1
(en)
|
2021-12-20 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
WO2023122762A1
(en)
|
2021-12-22 |
2023-06-29 |
Camp4 Therapeutics Corporation |
Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
|
WO2023122750A1
(en)
|
2021-12-23 |
2023-06-29 |
Synthorx, Inc. |
Cancer combination therapy with il-2 conjugates and cetuximab
|
WO2023127857A1
(ja)
*
|
2021-12-27 |
2023-07-06 |
株式会社理研ジェネシス |
新規人工核酸、その製造方法及び用途
|
WO2023141507A1
(en)
|
2022-01-20 |
2023-07-27 |
Genentech, Inc. |
Antisense oligonucleotides for modulating tmem106b expression
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
AR128558A1
(es)
|
2022-02-21 |
2024-05-22 |
Hoffmann La Roche |
Oligonucleótido antisentido
|
WO2023178144A2
(en)
|
2022-03-16 |
2023-09-21 |
Empirico Inc. |
Galnac compositions for improving sirna bioavailability
|
WO2023217890A1
(en)
|
2022-05-10 |
2023-11-16 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting cfp-elk1 intergene region
|
TW202409276A
(zh)
|
2022-05-18 |
2024-03-01 |
瑞士商赫孚孟拉羅股份公司 |
改良之靶向rna結合蛋白位點的寡核苷酸
|
WO2023240277A2
(en)
|
2022-06-10 |
2023-12-14 |
Camp4 Therapeutics Corporation |
Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
|
WO2023242324A1
(en)
|
2022-06-17 |
2023-12-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for targeting progranulin
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024040041A1
(en)
|
2022-08-15 |
2024-02-22 |
Dicerna Pharmaceuticals, Inc. |
Regulation of activity of rnai molecules
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
EP4332221A1
(en)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
WO2024050261A1
(en)
|
2022-08-29 |
2024-03-07 |
University Of Rochester |
Antisense oligonucleotide-based anti-fibrotic therapeutics
|
WO2024052403A1
(en)
|
2022-09-06 |
2024-03-14 |
F. Hoffmann-La Roche Ag |
Double-stranded rna molecule for administration to the eye
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024098061A2
(en)
|
2022-11-04 |
2024-05-10 |
Genkardia Inc. |
Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
|
WO2024098002A1
(en)
|
2022-11-04 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
WO2024119145A1
(en)
|
2022-12-01 |
2024-06-06 |
Camp4 Therapeutics Corporation |
Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
|
WO2024124041A1
(en)
|
2022-12-07 |
2024-06-13 |
Advanced Cell Diagnostics, Inc. |
Multiplexed detection of nucleic acid targets
|